Rebecca Velez Frey Email & Phone Number

Rebecca is a versatile CEO and board director with twenty five years of experience in drug development, manufacturing and leadership. Her experience spans a wide range of therapeutic areas and platforms in large pharma and small biotech, including having worked on the development and/or manufacturing of 10 now-approved products/indications. In 2021 she joined Siduma Therapeutics as President, CEO and director. She currently serves as an independent director on the boards of two biotech companies, Octant and Halda Therapeutics, and is Directorship Certified by the National Association of Corporate Directors (NACD.DC). Rebecca also serves as a part-time venture partner with Elm Street Ventures, a fund focused the Yale innovation ecosystem. She has previously held key operational leadership roles in biotech startups including EvolveImmune Therapeutics, Cardurion Pharmaceuticals and Prevail Therapeutics. Prior to these roles, she spent eleven years working in medical affairs, development, corporate affairs and manufacturing at Alexion Pharmaceuticals where she was credited with leading successful development programs, integrations and global enterprise projects. Earlier in her career she worked in development and medical affairs at Novartis Pharmaceuticals. Outside of her operating and governance roles, Rebecca is passionate about building strong bioscience communities. In 2024 she joined the board of directors of Latinos in Bio, a global nonprofit supporting the careers of Latinos in the life sciences. She co-founded Executive Women In Bio of CT. She is a also member of the Dean’s Advisory Board of Bouvé College of Health Sciences at Northeastern University in Boston. Rebecca earned a Doctor of Pharmacy from Northeastern University and completed a clinical fellowship at Tufts Medical Center. She also holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management.Rebecca was named to the 2023 New Haven "Power 25".

Listed skills include Pharmaceutical Industry, Program Management, Corporate Development, Strategic Planning, and 39 others.